Chapter 5. Pseudotyping of Adenoviral Vectors
- David T. Curiel M.D. and
- Joanne T. Douglas Ph.D.
Published Online: 31 MAR 2003
Copyright © 2002 John Wiley & Sons, Inc.
Vector Targeting for Therapeutic Gene Delivery
How to Cite
Havenga, M. J. E., Vogels, R., Bout, A. and Mehtali, M. (2003) Pseudotyping of Adenoviral Vectors, in Vector Targeting for Therapeutic Gene Delivery (eds D. T. Curiel and J. T. Douglas), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/0471234303.ch5
Division of Human Gene Therapy, Departments of Medicine, Pathology and Surgery, and the Gene Therapy Center, The University of Alabama at Birmingham, USA
- Published Online: 31 MAR 2003
- Published Print: 9 AUG 2002
Print ISBN: 9780471434795
Online ISBN: 9780471234302
- vector neutralisation;
- vector toxicity
Recombinant adenoviral vectors hold great promise as pharmaceutical drugs to treat or prevent a wide variety of human diseases. However, to increase clinical efficiency several issues need to be addressed. These are, amongst others, in vivo vector specificity and toxicity. This chapter describes strategies aimed at altering adenoviral vector design such as pseudotyping serotype 5 vectors with coat proteins derived from alternative serotypes. Such pseudotyped adenoviral vectors, that are not prone to neutralisation and that have high in vivo target specificity, in theory allow for a lower dose to be administered in vivo. Since a significant decrease in the therapeutic vector dose is considered to circumvent vector toxicity, this new generation of chimeric vectors may constitute an important step forwards in the generation of universally applicable vectors to battle human diseases.